← Find more feeds

investor.seagen.com

Seagen Press Releases

Get the latest updates from Seagen Press Releases directly as they happen.

Follow now 62 followers

Latest posts

Last updated 3 months ago

Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer

3 months ago

Read full

U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

3 months ago

Read full

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

3 months ago

Read full

Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance

3 months ago

Read full

Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial

3 months ago

Read full

Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium

3 months ago

Read full

Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

3 months ago

Read full

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

4 months ago

Read full

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

4 months ago

Read full

U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

5 months ago

Read full

Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts

5 months ago

Read full

Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance

5 months ago

Read full

Or log in

Everything you care about in one place

Seagen Press Releases

Latest posts

Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer

U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance

Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial

Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium

Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts

Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance

Try Feeder for free